Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Admission to coronary ICU~* Admission blood glucose 140-299 mg/dL~* Primary cardiovascular diagnosis by attending physician~* Under primary care of cardiology service~* Age \> 18 years old~* Ventilator independent~* Able to provide informed consent~Exclusion Criteria:~* Admission blood glucose \< 140 or \> 300 mg/dL~* Ventilator dependent~* Unconscious sedation~* Type 1 diabetes~* Known pregnancy~* Admitted to coronary ICU for right heart cath to measure hemodynamics prior to transplant~* Post transplant procedure~* Currently enrolled in another clinical trial~* Unable to provide informed consent~* Creatinine clearance \< 30 mL/min~* On insulin treatment except for monotherapy with long-acting basal insulin (e.g., insulin glargine \[Lantus®\] or detemir \[Levemir®\])~* Gastroparesis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: EXPERIMENTAL): 0.05 µg/min liquid bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).